Immunology Investor Event

Dupixent: Asthma 6-11yo Prevalence Number of patients (thousands) Treated 201 180 381 Biologics eligible 75 26 101 2,365 1,253 3,618 Moderate to severe with persistent use of medium to high dose ICS or OCS use or biologic 0 500 2,000 2,500 3,000 3,500 4,000 US Europe(1) Source: Sanofi analysis ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids (1) Germany, France, Italy, Spain & United Kingdom (2) For Europe, severe uncontrolled type 2 7 Immunology Investor Event Uncontrolled despite persistent use of medium to high dose ICS + ≥1 controller or OCS(2) sanofi

View entire presentation